L
Lacerta Therapeutics
Clinical stage gene therapy for central nervous system
About Lacerta Therapeutics
Lacerta Therapeutics is a clinical-stage gene therapy company specializing in the development, production, and application of adeno-associated virus (AAV) vector technologies. The company focuses on creating treatments for central nervous system and lysosomal storage diseases. Lacerta Therapeutics serves pharmaceutical companies, research institutions, and healthcare providers by offering early access to novel capsid variant identification and scalable AAV vector manufacturing. The business operates in the biotechnology and healthcare markets, leveraging its unmatched scientific expertise to advance clinical programs. Lacerta Therapeutics generates revenue through collaborative partnerships, out-licensing opportunities, and the development of proprietary treatments. The company's business model is built on providing innovative solutions that offer numerous advantages over current AAV vector platforms. Keywords: gene therapy, AAV vectors, neurological diseases, lysosomal storage, biotechnology, healthcare, scalable manufacturing, clinical-stage, proprietary technologies, partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Alachua, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 58.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Lacerta Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2018 | $30M | $120M | Undisclosed | ↗ |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | University of Florida | — |
Growth signals
Latest recorded traffic for Lacerta Therapeutics is 0 monthly website visits, down 100% over the last three months. Lacerta Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
University of Florida
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lacerta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lacerta Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.